Pre-eclampsia prediction and prevention infrastructure matures
sFlt-1 to PlGF ratio testing in suspected pre-eclampsia and aspirin-prophylaxis pathway adoption are reshaping pre-eclampsia care.
Pre-eclampsia prediction has historically been clinical and inconsistent. The sFlt-1 to PlGF ratio biomarker test has approval and growing use in suspected pre-eclampsia for short-term outcome prediction. First-trimester pre-eclampsia screening combining maternal factors, blood pressure, biomarkers, and uterine artery Doppler enables targeted aspirin prophylaxis in high-risk patients. Together these reshape the pre-eclampsia care pathway materially.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.